Molecular imaging and radionuclide therapy of neuroendocrine tumors

Area of Science:

• Oncology
• Nuclear Medicine
• Radiotherapy

Background:

• Neuroendocrine tumors (NETs) are diverse neoplasms with unpredictable prognoses.
• Most well-differentiated NETs exhibit somatostatin receptor expression.
• Somatostatin receptors are crucial targets for advanced diagnostic and therapeutic strategies.

Purpose of the Study:

• To review the advancements in molecular imaging and targeted radiotherapies for neuroendocrine tumors.
• To highlight the role of somatostatin receptors in NET diagnosis and treatment selection.
• To discuss the emerging field of theranostics in NET management.

Main Methods:

• Review of current literature on molecular imaging techniques for NETs.
• Analysis of somatostatin receptor-based diagnostic and therapeutic modalities.
• Evaluation of recent clinical studies on peptide receptor radionuclide therapy (PRRT).

Main Results:

• Molecular scans provide critical diagnostic, staging, and prognostic information for NETs.
• Somatostatin-receptor imaging effectively identifies patients suitable for targeted therapies.
• Peptide receptor radionuclide therapy has shown significant efficacy in progressive midgut NETs.

Conclusions:

• Molecular imaging is an increasingly vital tool in NET management, offering diagnostic and prognostic value.
• Theranostics, combining imaging and targeted therapy, represents a promising frontier in personalized cancer treatment.
• Ongoing research focuses on novel receptor-targeting agents, isotopes, and combination therapies to enhance NET treatment efficacy.